Baxter International lists 10 executives, led by Andrew P. Hider, CEO, Pres., Interim Group Pres. of Medical Products & Therapies and Director (age 48). John Terence Rogers is the company's Executive VP & CFO (age 56).
In fiscal year 2025 the highest-paid executive was Andrew P. Hider, CEO, Pres., Interim Group Pres. of Medical Products & Therapies and Director, with total pay of $3.49 million. The 3 executives with reported pay received $5.77 million in all.
The average age of the executives with a known age is 54; the youngest is 39 and the oldest 65.
Titles, ages and pay from company filings; pay for fiscal year 2025.

CEO, Pres., Interim Group Pres. of Medical Products & Therapies and Director
Executive VP & General Counsel
Group President of Infusion Therapies & Platforms
Executive VP & CFO
Interim Chief Accounting Officer & Controller
Senior VP & Chief Information Officer
Vice President & Head of Investor Relations
SVP, Chief Communications Officer & Corporate Marketing and President of Baxter Foundation
Executive VP & Chief Human Resources Officer
Executive VP & Chief Supply Chain Officer
| Executive | Title | Age | Total pay |
|---|---|---|---|
| Andrew P. Hider | CEO, Pres., Interim Group Pres. of Medical Products & Therapies and Director | 48 | $3.49 million |
| David S. Rosenbloom | Executive VP & General Counsel | 65 | $1.18 million |
| Maria Soriano | Group President of Infusion Therapies & Platforms | – | $1.10 million |
Total pay as reported for the fiscal year; it can include salary, bonus and stock awards.
Andrew P. Hider (CEO, Pres., Interim Group Pres. of Medical Products & Therapies and Director), age 48; total pay in fiscal year 2025 was $3.49 million.
John Terence Rogers (Executive VP & CFO), age 56.
Andrew P. Hider, CEO, Pres., Interim Group Pres. of Medical Products & Therapies and Director, with total pay of $3.49 million in fiscal year 2025.
Andrew P. Hider (CEO, Pres., Interim Group Pres. of Medical Products & Therapies and Director), David S. Rosenbloom (Executive VP & General Counsel), Maria Soriano (Group President of Infusion Therapies & Platforms), John Terence Rogers (Executive VP & CFO) and Bernie Heine (Interim Chief Accounting Officer & Controller), and 5 more.